By Fineline Cube 
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced the completion of patient enrollment for the first pivotal Phase III LUGANO study of Duravyu (formerly EYP-1901), an investigational treatment for wet age-related macular degeneration (wet AMD). This milestone marks a significant step forward in the development of this innovative ophthalmic therapy.
Duravyu Technology
Duravyu leverages EyePoint’s proprietary Durasert E sustained-release technology to deliver vorolanib, a tyrosine kinase inhibitor, as a solid, biodegradable intraocular implant. This advanced delivery system is designed to provide sustained drug release and improved patient compliance.
Licensing Agreement with Betta Pharmaceuticals
In May 2022, Betta Pharmaceuticals secured exclusive rights to develop and commercialize Duravyu in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) through a licensing agreement with EyePoint. EyePoint retains global rights for other ophthalmic indications, ensuring a broad development and commercialization strategy for Duravyu.-Fineline Info & Tech